Design of carriers to aid intracellular delivery of agents can greatly improve medical treatments.
INTRODUCTION
Safe and efficient intracellular drug delivery remains a major challenge since most agents cannot cross cell membranes, including the plasmalemma and endocytic vesicles 1 . This prevents access to the cell cytosol and other intracellular compartments. Numerous strategies aim to overcome this limitation, including those that employ cell-penetrating or fusogenic peptides, peptidomimetics, toxins, synthetic or natural polycationic polymers or lipids, capitalize on the proton sponge effect or volume changes within endosomes, etc 1 . Yet, intracellular delivery remains elusive and aspects requiring optimization relate to the safety, specificity, and mechanism of action of these approaches.
DNA represents an alternative material toward this goal. DNA can be engineered into any architecture, its synthesis/assembly as well as disassembly/degradation can be controlled by chemical, enzymatic and physical means, it is water soluble, biodegradable, can interact with positivelycharged cargoes and solubilize hydrophobic drugs, and can be modified with any functional element 2 . Although still very scarce (less than a dozen publications), recent studies have shown great promise for DNA-based drug delivery systems.
However, most previous works have employed DNA-devices which: (a) contained an additional material as a part of their structural scaffold (lipidic, polymeric, inorganic, etc.), [3] [4] [5] [6] (b) had sizes small enough so that they may not be able to avoid nonspecific penetration through certain tissues (≤ 20-nm) 5, 7 or were too large to enter non-immune cells by endocytosis (macro-assemblies), 2, 3 and/or (c) were shown to bind and gain access into cells largely by non-specific pathways (scavenger receptors, macropinocytosis, etc.) 4, 5, 8 even when targeted to selected cell-surface receptors. 5 The study presented here has explored intracellular delivery of diverse compounds (model drugs and biologicals) mediated by DNA-devices void of other structural materials, large enough to avoid broad penetration through tissues yet still small enough to allow endocytosis, and with enough selectivity toward molecular targets as to overcome non-specific receptors and endocytic pathways.
EXPERIMENTAL METHODS
To determine if DNA-devices can provide cell targeting and endocytosis via selected cell-surface receptors and pathways, DNA dendrimers were tested. These consist of DNA modules self assembled by complementarity to contain a core and a selected number of layers (generations). These devices have been used as scaffolds for signal amplification, 9 but have not been tested for drug delivery. As a control for lack of endosomal escape, polystyrene nanoparticles (NPs) were used. 10 Generation 4 DNA dendrimers (nucleodendrimers (NDs)) or polymer NPs of similar size were coated with non-specific IgG or antibodies against specific cell surface receptors. 10 Binding to cells in culture, endocytosis, endosomal escape, delivery to different subcellular compartments, cargo effect, and cell viability were tested by fluorescence microscopy.
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RESULTS AND DISCUSSION
NDs were coupled to an antibody recognizing intercellular adhesion molecule-1 (ICAM-1). This is a protein expressed on many cell types in pathological estates, well-studied in drug delivery. 10 Antibody coating increased ND size from 175.4±9.2-nm to 211.3±13.9-nm, measured by DLS. Within 1h, anti-ICAM NDs bound to cells with high specificity (~190 NDs/cell; ~190-fold over IgG NDs), comparably to anti-ICAM NPs of similar size. Anti-ICAM NDs were efficiently internalized by cells (~82% of bound NDs; undetectable for control IgG NDs), in a similar manner to anti-ICAM NPs. Uptake of both carrier types was similarly inhibited at 4°C (20% uptake) and inhibitors of ICAM-1-dependent endocytosis (amiloride; 20% uptake), but not inhibitors of caveoli (71% uptake), clathrin (70% uptake), or macropinocytosis (85% uptake). This indicates that receptor-mediated binding and endocytosis of NDs is highly selective and similar to that of polymer NPs.
However, intracellular distribution of anti-ICAM NDs was different from that of anti-ICAM NPs: NPs accumulated in the perinuclear region of cells (~70% of carriers; 1h), in agreement with their known lysosomal routing. 10 In contrast, anti-ICAM NDs appeared scattered throughout the cell body even after 3h (~40% perinuclear). This suggests that NDs provide for a different trafficking route, perhaps endosomal escape, as reported for other DNA devices. [4] [5] [6] In agreement with this hypothesis, texasred dextran, which had been incorporated similarly into endocytic vesicles containing anti-ICAM NPs or anti-ICAM NDs (~60 vesicles/cell), was released into the cytosol in the case of NDs but not NPs. The number of dextran-positive endosomes and area occupied by dextran remained the same with time for anti-ICAM NPs. However, in the case of anti-ICAM NDs the number of dextran-positive endosomes was reduced by ~2-fold by 3h and the area occupied by released dextran doubled. Although the mechanism remains uncharacterized, this agrees with the fact that DNA "packed" in particular architectures can become protonated at endo-lysosomal pH, suffering volume changes and leading to interaction with membranes, providing a possible mechanism for endosomal escape. 5 To then explore if NDs can provide intracellular delivery, a series of tests were performed, verifying that only anti-ICAM NDs, not NPs, delivered cargoes within cells. These cargoes included: a) phalloidin, a drug that was able to interact with Factin in the cytosol; b) albumin-nuclear-localizationsignal fusion protein, which was able to traffic to the cell nucleus; c) EGFP-RhoA plasmid, which was able to transfect cells and render plasmid expression; and d) catalase enzyme, which escaped endolysosomal-associated proteolyisis and was able to protect cells against H 2 O 2 -induced oxidative injury.
Despite providing endosomal escape, NDs did not affect the cell viability. NDs could be efficiently targeted to other receptors, e.g. platelet-endothelial adhesion molecule 1, which is also associated with CAM-mediated endocytosis, or the transferrin receptor or mannose-6-phosphate receptor, which are associated with clathrin-mediated uptake. NDs could target receptors on diverse cell types, including endothelial, epithelial, REN and fibroblast cells; primary and established cell cultures; healthy, inflammation or cancer cell models.
CONCLUSION
DNA-devices of size viable for endocytosis and sufficient targeting valency can provide: (a) specific binging to selected cell-surface markers, (b) efficient endocytosis into cells via the associated pathway, (c) cytosolic delivery of a broad range of compounds (drugs, sugars, proteins, nucleic acids), (d) access to other intracellular compartments (e.g. the nucleus), and (e) functional intracellular effects, (f) without apparent cytotoxicity. This is the first time that a DNA-built nanocarrier shows true specificity toward both the target receptor and uptake pathway selected, while providing safe endosomal escape and delivery of diverse compounds intracellularly. Hence, DNAdevices hold great potential for intracellular drug delivery, further shifting the now questionable paradigm of DNA being unable to enter cells.
